Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)

Abstract

IntroductionSeveral observational studies suggest that statins modulate the pathophysiology of sepsis and may prevent its progression. The aim of this study was to determine if the acute administration of atorvastatin reduces sepsis progression in statin naïve patients hospitalized with sepsis.MethodsA single centre phase II randomized double-blind placebo-controlled trial. Patients with sepsis were randomized to atorvastatin 40 mg daily or placebo for the duration of their hospital stay up to a maximum of 28-days. The primary end-point was the rate of sepsis progressing to severe sepsis during hospitalization.Results100 patients were randomized, 49 to the treatment with atorvastatin and 51 to placebo. Patients in the atorvastatin group had a significantly lower conversion rate to severe sepsis compared to placebo (4% vs. 24% p = 0.007.), with a number needed to treat of 5. No significant difference in length of hospital stay, critical care unit admissions, 28-day and 12-month readmissions or mortality was observed. Plasma cholesterol and albumin creatinine ratios were significantly lower at day 4 in the atorvastatin group (p < 0.0001 and p = 0.049 respectively). No difference in adverse events between the two groups was observed (p = 0.238).ConclusionsAcute administration of atorvastatin in patients with sepsis may prevent sepsis progression. Further multi-centre trials are required to verify these findings.Trial RegistrationInternational Standard Randomized Control Trial Registry ISRCTN64637517.

Statin as an Anti-Inflammatory Agent in Sepsis

“…Evidences suggested that statin therapy reduces six times the incidence in severe sepsis [5], three times developing pneumonia in diabetic patients [68], 2.5 times hospital admission for sepsis in patients with chronic renal failure [69], reduces 7.9 times the developing severe sepsis due to acute bacterial infection [6], reduce 19-25% incidence of sepsis in patients with cardiovascular disease [70]. A recent study also showed that acute atorvastatin administration may prevent sepsis progression in patient with sepsis [71]. However mortality rate didn't reduce by statin using in this study.…”

Statins in patients with sepsis and ARDS: is it over? No

“…Statin use prior to the development of multiple organ failure may in part explain the discordance between observational studies (including patients who were on statins before their critical illness) with randomised trials (including patients with established organ failure). Of note a study by Patel et al [14] suggests a lower rate of progression of sepsis with atorvastatin compared to placebo. Fortunately further studies assessing if statin therapy may have a preventive role very early in an illness or even as prophylaxis are now starting.…”

The controversy over H5N1 transmissibility research

“…Investigators will have to decide whether the trials should be restricted to ICU-admitted patients, who might not benefit, 76,77,113 or include all hospitalized patients at risk of rapidly developing more serious illness. 79 Regardless of their design, the trials will be expensive, so animal studies comparing different immunomodulatory agents will be needed to guide the choice of which agent(s) to evaluate in clinical trials.…”